Data-driven analysis backed by 1,400+ primary-sourced biopharma transactions. Licensing benchmarks, negotiation strategies, and market intelligence.
Small molecule deal activity exploded from zero to 70 transactions in six months — a 7000% surge that represents the sharpest modality-level acceleration we've tracked in 2026. Here's what's behind it, who's buying, and what it means for your next term sheet.
Other modality deals jumped from 7 to 96 in six months — a 1271% increase that reflects Big Pharma's aggressive push beyond traditional small molecules and biologics. The Omeros-Novo Nordisk ($2.4B TDV) and CSPC-AstraZeneca ($18.5B TDV) deals anchor a trend that BD teams can no longer treat as noise.
Hematology licensing went from zero deals to 16 in six months — a 1600% spike driven by Big Pharma pipeline anxiety and a single $2B mega-deal from Incyte. Here's what the data says and what it means for your next negotiation.
Vaccine deal activity exploded from zero transactions to 17 in six months — a 1700% surge driven by Big Pharma pipeline anxiety and next-gen platform bets. Eli Lilly and Sanofi are leading the charge with multi-billion-dollar total deal values. Here's what BD teams need to know right now.
Bispecific antibody licensing activity exploded from 1 deal to 19 deals in six months — an 1800% surge. Pfizer alone committed over $12.5B in total deal value across two 3SBio transactions. Here's what's driving the spike and what it means for BD teams negotiating right now.
ADC licensing activity surged 1900% between February and August 2026, jumping from 1 deal to 20. GSK, Novartis, and a wave of mid-cap buyers are driving the most aggressive ADC deal cycle in a decade — and the structural implications for BD teams are significant.
Small molecule licensing activity exploded 3067% between the first and second halves of the trailing twelve months, jumping from 3 deals to 95. The data points to a structural shift in Big Pharma pipeline strategy — and the deal tables from July 2026 confirm it.
Rare disease deal activity exploded 3400% between February and August 2026, jumping from 1 deal to 35. Five deals alone exceeded $1.9B in total deal value. Here's what's driving it, who's buying, and what BD teams should do right now.
Deal activity in the 'other' category — spanning tools, platforms, diagnostics, and enabling technologies — jumped 3400% in the first half of 2026, going from zero deals to 34. Merck KGaA's $11.3B Bio-Techne acquisition and Pfizer's $2B YaoPharma licensing deal anchor a trend that reshapes how BD teams should think about non-traditional therapeutic assets.
Mega-deal activity exploded from zero to 61 transactions between February and August 2026 — a 6100% increase. We break down the drivers, the landmark deals, and what this means for BD teams negotiating billion-dollar structures right now.
Other modality deals jumped from 7 to 96 in six months — a 1271% increase that represents the most dramatic category surge in 2026 dealmaking. The data points to Big Pharma aggressively filling pipeline gaps in non-traditional modalities, and the deal structures reflect it.
Oncology deal activity exploded from 5 transactions to 79 in six months — a 1480% increase that signals a fundamental reset in how Big Pharma is sourcing pipeline assets. The data points to a seller's market with no signs of cooling.
Hematology deal activity exploded from zero transactions to 16 in six months — a 1600% increase that signals a fundamental shift in Big Pharma pipeline strategy. The Incyte-Vega Therapeutics deal alone carried a $2B total deal value. Here's what's driving the surge and what it means for BD teams negotiating hematology licensing in 2026.
Vaccine deal activity exploded 1700% in the first half of 2026, jumping from zero transactions to 17 in six months. Eli Lilly and Sanofi are leading a land grab that's reshaping vaccine licensing 2026 dynamics — and BD teams need to recalibrate now.
Bispecific antibody licensing activity jumped from 1 deal to 19 in six months — an 1800% surge driven by Big Pharma pipeline anxiety and platform-level acquisitions. Here's what the data says and what it means for your next negotiation.
ADC licensing activity exploded by 1900% between February and August 2026, jumping from 1 deal to 20 in a single six-month window. GSK, Novartis, and Whitehawk led the charge with multi-billion-dollar total deal values. Here's what's driving it and what it means for your next negotiation.
Small molecule licensing activity exploded from 3 deals to 95 in six months — a 3067% increase. The surge is driven by Big Pharma pipeline anxiety, degrader platform maturation, and a strategic pivot away from biologics risk. Here's what the data says and what BD teams should do about it.
Rare disease licensing activity exploded by 3400% in the first half of 2026, jumping from 1 deal to 35 in a single six-month period. Five deals alone cleared $1.9B in total deal value. Here's what's driving the surge and what it means for your next negotiation.
Other licensing 2026 has exploded from zero deals to 34 in six months — a 3400% increase driven by platform technology acquisitions and cross-therapeutic partnerships. The Bio-Techne/Merck KGaA mega-deal alone signals a structural shift in how pharma values enabling technologies.
Mega-deal activity exploded from zero to 61 transactions between February and August 2026 — a 6100% surge. We dissect the drivers, the standout deals, and the tactical implications for every BD team in biopharma.
Mega-deal activity exploded from zero to 61 transactions in the first half of 2026 — a 6100% increase period over period. Eli Lilly, GSK, and Ipsen are leading a land grab that's reshaping deal structures and leverage dynamics across biopharma BD.
Other deal activity jumped 3600% in the first half of 2026, leaping from zero recorded deals to 36 in six months. Mega-transactions like Merck KGaA's $11.3B Bio-Techne acquisition and Pfizer's $2B YaoPharma licensing deal are rewriting the playbook for cross-category dealmaking.
Mega-deal activity exploded from zero to 61 transactions between February and August 2026 — a 6100% surge that rewrites the competitive playbook for BD teams. Here's what's behind it and what it means for your next negotiation.
Mega-deal activity exploded from zero to 61 transactions in the first half of 2026 — a 6100% increase. Eli Lilly, GSK, and Ipsen are leading the charge. Here's what's driving the surge and what it means for BD teams right now.
Deal activity classified as "other" — including platform technology acquisitions, tools licensing, and cross-sector partnerships — surged 3900% in the first half of 2026. Merck KGaA's $11.3B Bio-Techne deal and Pfizer's $2B YaoPharma partnership signal a structural shift in how pharma is sourcing innovation.
Get data-driven deal terms for any therapeutic area, modality, and clinical phase. Powered by 1,400+ primary-sourced biopharma transactions.
Try Solidus
